Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Merck KGaA's USD 11.3b Bio-Techne acquisition clears final shareholder approval hurdle

23 September 2026 · By · Wire by Fusion42

Published

23 September 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 24 September 2026 · Fusion42 review

Merck KGaA received final shareholder approval to acquire Bio-Techne for USD 11.3 billion, marking its largest life sciences deal since 2015. The acquisition enhances Merck's position in life science tools critical for biologics and advanced therapy manufacturing, with closing expected by early 2027 after regulatory approvals.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

Your biotech supply chain just contracted under a larger corporate umbrella. You need to reconsider partnerships and customer positioning as Merck expands its life sciences tools influence.

◆ Coverage

2 sources · 23 Sep 2026

◆ Related on Wire

◆ Topics

Biotechmerck-kgaabio-technem-alife-sciencesregulatory-approval